Asset Details
Do you wish to reserve the book?
Correlation of Serum Cancer Antigen-125 (CA-125) Levels with Severity of Pre-eclampsia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Correlation of Serum Cancer Antigen-125 (CA-125) Levels with Severity of Pre-eclampsia
Do you wish to request the book?
Correlation of Serum Cancer Antigen-125 (CA-125) Levels with Severity of Pre-eclampsia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Correlation of Serum Cancer Antigen-125 (CA-125) Levels with Severity of Pre-eclampsia
2023
Overview
Background
Pre-eclampsia is often associated with unfavourable feto-maternal outcomes. There is a lacuna in its pathophysiology, which emphasizes the need to research for tests, which can predict or correlate with the severity of pre-eclampsia. Cancer antigen-125 (CA-125) is a simple, readily available biomarker with evidence of its secretion at the choriodecidual unit and may have a possible role. This study compared serum CA-125 levels between normal pregnant and pre-eclamptic women and determined its clinical usefulness in correlating with the severity of pre-eclampsia.
Methods
A case–control study was conducted enrolling 58 women with pre-eclampsia further divided into severe and non-severe groups and 62 gestational age-matched healthy, pregnant controls. Serum CA-125 levels were compared between the two groups.
Results
The mean serum CA-125 in the controls was 16.44 ± 8.28 IU/ml, 13.82 ± 9.18 IU/ml in the non-severe and 23.55 ± 30.55 IU/ml in the severe pre-eclampsia group (
p
= 0.134). Serum CA-125 had a significant association with systolic blood pressure (SBP)
p
= 0.002), diastolic blood pressure (DBP) (
p
= 0.026), foetal growth restriction (
p
= 0.025), pre-term birth (
p
= 0.039) and a highly significant association with 24-h urinary protein, liver enzymes, placental abruption, need of maternal intensive care as well as with poor neonatal outcome including stillbirth and neonatal mortality (
p
< 0.001).
Conclusion
Serum CA-125 levels were found to be higher in the severe pre-eclampsia group as compared to non-severe pre-eclampsia and normotensive group, but the difference was not statistically significant. More studies on a larger scale are required to prove the usefulness of this marker with respect to maternal and perinatal outcome as well as its association with pre-eclampsia and its severity.
Publisher
Springer India,Springer Nature B.V
